Julia White, MD

The professor of radiation oncology discussed these tailored treatments for when patients receive neoadjuvant chemotherapy, and they get a complete pathologic response.

There is a need to learn more about the effect of hypofractionation on an individual patient’s breast cancer outcomes and tissue toxicities, based on both biologic and technical variables, so that the treatment decision is not primarily a matter of dollars and cents.

The DCIS Score provides clinically relevant information about personal risk that can guide patient discussions and facilitate shared decision making.